[Source: US National Library of Medicine, full page: (LINK). Abstract, edited.]
Mol Ther. 2019 Mar 28. pii: S1525-0016(19)30091-7. doi: 10.1016/j.ymthe.2019.03.005. [Epub ahead of print]
In Vivo Delivery of a DNA-Encoded Monoclonal Antibody Protects Non-human Primates against Zika Virus.
Esquivel RN1, Patel A1, Kudchodkar SB1, Park DH1, Stettler K2, Beltramello M2, Allen JW3, Mendoza J3, Ramos S3, Choi H1, Borole P1, Asija K1, Bah M1, Shaheen S1, Chen J3, Yan J3, Durham AC4, Smith TRF3, Broderick K3, Guibinga G3, Muthumani K1, Corti D2, Humeau L3, Weiner DB5.
Author information: 1 Vaccine & Immunotherapy Center, The Wistar Institute of Anatomy & Biology, Philadelphia, PA, USA. 2 Humabs BioMed: a subsidiary of Vir Biotechnology, Bellinzona, Switzerland. 3 Inovio Pharmaceuticals, Plymouth Meeting, PA, USA. 4 Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, PA, USA. 5 Vaccine & Immunotherapy Center, The Wistar Institute of Anatomy & Biology, Philadelphia, PA, USA. Electronic address: email@example.com.
Zika virus (ZIKV) infection is endemic to several world regions, and many others are at high risk for seasonal outbreaks. Synthetic DNA-encoded monoclonal antibody (DMAb) is an approach that enables in vivo delivery of highly potent mAbs to control infections. We engineered DMAb-ZK190, encoding the mAb ZK190 neutralizing antibody, which targets the ZIKV E protein DIII domain. In vivo-delivered DMAb-ZK190 achieved expression levels persisting >10 weeks in mice and >3 weeks in non-human primate (NHPs), which is protective against ZIKV infectious challenge. This study is the first demonstration of infectious disease control in NHPs following in vivo delivery of a nucleic acid-encoded antibody, supporting the importance of this new platform.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.
KEYWORDS: DMAb; DNA; DNA-encoded monoclonal antibody; Zika virus; antibody; immunoprophylaxis; infectious diseases; protection; rhesus macaque
PMID: 30962164 DOI: 10.1016/j.ymthe.2019.03.005
Keywords: Monoclonal antibodies; Zika Virus; Animal models.